Castle Biosciences Past Earnings Performance
Past criteria checks 0/6
Castle Biosciences's earnings have been declining at an average annual rate of -42.5%, while the Healthcare industry saw earnings growing at 7.1% annually. Revenues have been growing at an average rate of 36.8% per year.
Key information
-42.5%
Earnings growth rate
-28.3%
EPS growth rate
Healthcare Industry Growth | 8.5% |
Revenue growth rate | 36.8% |
Return on equity | -0.7% |
Net Margin | -1.1% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Castle Biosciences: Inflection Into Profitability
Aug 16Upgrade: Analysts Just Made A Meaningful Increase To Their Castle Biosciences, Inc. (NASDAQ:CSTL) Forecasts
Aug 11Castle Biosciences, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
Aug 08Castle Biosciences, Inc.'s (NASDAQ:CSTL) 28% Share Price Surge Not Quite Adding Up
Aug 04Is Castle Biosciences (NASDAQ:CSTL) A Risky Investment?
Jul 12Castle Biosciences, Inc.'s (NASDAQ:CSTL) P/S Is On The Mark
Apr 30Investors Appear Satisfied With Castle Biosciences, Inc.'s (NASDAQ:CSTL) Prospects
Jan 27Castle Biosciences (NASDAQ:CSTL) Is In A Good Position To Deliver On Growth Plans
Oct 31Earnings Working Against Castle Biosciences, Inc.'s (NASDAQ:CSTL) Share Price Following 36% Dive
Jun 13Analysts Just Published A Bright New Outlook For Castle Biosciences, Inc.'s (NASDAQ:CSTL)
Aug 14Castle Biosciences Q2 2022 Earnings Preview
Aug 08Is There Now An Opportunity In Castle Biosciences, Inc. (NASDAQ:CSTL)?
Aug 05Revenue & Expenses Breakdown
How Castle Biosciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 288 | -3 | 188 | 54 |
31 Mar 24 | 251 | -31 | 182 | 53 |
31 Dec 23 | 220 | -57 | 180 | 54 |
30 Sep 23 | 192 | -76 | 174 | 52 |
30 Jun 23 | 168 | -89 | 168 | 50 |
31 Mar 23 | 152 | -72 | 159 | 49 |
31 Dec 22 | 137 | -67 | 143 | 45 |
30 Sep 22 | 124 | -53 | 130 | 43 |
30 Jun 22 | 110 | -44 | 114 | 40 |
31 Mar 22 | 98 | -52 | 99 | 34 |
31 Dec 21 | 94 | -31 | 87 | 30 |
30 Sep 21 | 86 | -30 | 77 | 25 |
30 Jun 21 | 78 | -23 | 66 | 20 |
31 Mar 21 | 68 | -15 | 55 | 16 |
31 Dec 20 | 63 | -10 | 48 | 13 |
30 Sep 20 | 63 | -3 | 43 | 12 |
30 Jun 20 | 63 | 7 | 38 | 10 |
31 Mar 20 | 61 | 6 | 35 | 9 |
31 Dec 19 | 52 | 3 | 30 | 7 |
30 Sep 19 | 46 | 4 | 24 | 5 |
30 Jun 19 | 35 | -6 | 21 | 5 |
31 Mar 19 | 28 | -8 | 18 | 5 |
31 Dec 18 | 23 | -10 | 16 | 5 |
31 Dec 17 | 41 | -46 | 46 | 13 |
Quality Earnings: CSTL is currently unprofitable.
Growing Profit Margin: CSTL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CSTL is unprofitable, and losses have increased over the past 5 years at a rate of 42.5% per year.
Accelerating Growth: Unable to compare CSTL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CSTL is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (6%).
Return on Equity
High ROE: CSTL has a negative Return on Equity (-0.73%), as it is currently unprofitable.